Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat plus lenalidomide and dexamethasone dose-escalation study in relapsed multiple myeloma
2006-007030-35Phase 2Terminated
- Sponsor
- Novartis
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panobinostat in multiple myeloma (MM), sponsored by Novartis. Primary endpoint: Maximum tolerated dose of panobinostat. Started Oct 2007; status: terminated.
02
Drugs
panobinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2006-007030-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-007030-35.